Alerta

用于共递送AR siRNA和RSL3的靶向纳米粒子及其制备方法和应用

Resumen de: CN122537391A

本发明涉及靶向药物领域，公开了用于共递送AR siRNA和RSL3的靶向纳米粒子，由内向外包括内核和外膜，外膜包裹在内核外形成核‑壳结构纳米共递送系统，其中，内核以磷酸钙纳米簇为核心，且通过核心负载有负电性的siAR；外膜为负载有疏水性RSL3的阳离子脂质体膜，且阳离子脂质体膜表面修饰有前列腺特异性膜抗原（PSMA）靶向肽。以经优化的非典型晶体结构磷酸钙纳米簇为核心，可在中性pH环境下稳定共载负电性siAR，在肿瘤弱酸性微环境中快速溶解，实现药物pH响应性智能释放；外层包裹阳离子脂质体膜，既可稳定纳米结构、赋予正电性以促进细胞摄取，还可负载疏水性RSL3；最外层通过PEG长链偶联PSMA高亲和力靶向肽，赋予纳米粒主动肿瘤靶向能力。

一种用于促进跟腱损伤修复的可溶性微针贴片

Resumen de: CN122537290A

本发明属于生物医药技术领域，具体公开了一种用于促进跟腱损伤修复的可溶性微针贴片。该可溶性微针贴片包括基底以及在基底表面阵列式排布的可溶性微针，其中可溶性微针内负载有核壳结构的仿生靶向颗粒，仿生靶向颗粒的外壳为跟腱肌腱细胞来源的细胞膜囊泡，其核为负载有Purmorphamine的活性氧响应性纳米粒。在跟腱损伤小鼠模型中，该微针贴片中的仿生靶向纳米颗粒能够有效富集并长效滞留于损伤部位，并在高活性氧环境中响应性释放药物，进而促进Ⅰ型胶原合成、抑制Ⅲ型胶原沉积，减轻跟腱损伤区域的异位骨化程度，最终促进跟腱损伤的修复。

抗结直肠癌的siCAD、活性纳米颗粒、药物、制备和应用

Resumen de: CN122542541A

本发明属于抗癌药物领域，具体涉及抗结直肠癌的siCAD、活性纳米颗粒、药物、制备和应用，所述的抗结直肠癌的siCAD为具有SEQ ID NO.1~SEQ ID NO.3中的至少一种序列的siRNA；SEQ ID NO.1：GTATGAGGGTCTCTTCTTA；SEQ ID NO.2：GCTCTAGCGTTGAATTTGA；SEQ ID NO.3：GTGATCGACTCTACTTTGA。本发明还包括含有所述siCAD的抗结直肠癌的活性纳米颗粒。本发明研究表明，所述的siCAD可基于CAD的抑制实现结直肠癌的有效抑制和治疗。

一种多羟基可电离脂质、脂质纳米粒组合物与应用

Resumen de: CN122541324A

本发明涉及一种多羟基可电离脂质、脂质纳米粒组合物与应用。所述多羟基可电离脂质具有以下结构通式：；式中：R1选自取代或未取代的C10‑C30饱和烷基或不饱和烷基；R2选自取代或未取代的C2‑C15饱和烷基或不饱和烷基。与现有技术相比，本发明制得的多羟基可电离脂质及脂质纳米粒组合物可广泛应用于核酸递送载体、基因治疗药物及mRNA疫苗的制备。

一种氧缺陷二氧化钼基自组装靶向纳米平台及其制备方法和应用

Resumen de: CN122537323A

本申请提供了一种氧缺陷二氧化钼基自组装靶向纳米平台及其制备方法和应用。以表面带正电荷的氧缺陷二氧化钼纳米粒子为核心层，依次在核心层的表面包覆带负电的透明质酸层、带正电的聚赖氨酸层，形成具有核‑壳结构的MoO2@HA@PLL复合物。本发明不仅是简单地赋予氧缺陷二氧化钼以靶向和成像功能，更是要针对该特定材料的独特性质，克服从现有技术中无法直接获得启示的障碍，通过创新的组装顺序构建独特的结构（MoO2@HA@PLL），并实现一种更优的、不依赖酶激活的靶向摄取机制，最终获得一种性能卓越、机制先进的新型诊疗一体化纳米平台。

一种阿帕他胺纳米粒及其制备方法

Resumen de: WO2025140501A1

An apalutamide nanoparticle and preparation method therefor relating to the field of pharmaceutical preparations. The nanoparticle comprises an active ingredient and a stabilizer. The active ingredient is amorphous apalutamide or a pharmaceutically acceptable salt thereof, and the stabilizer comprises an ionic stabilizer and a steric stabilizer. The provided nanoparticle has a stable physical form, is able to stably maintain an amorphous crystal form, has good dissolution speed and dissolution rate, possesses good stability in terms of dissolution, content, related substances, crystal form, etc., and has good bioavailability.

脂质递送载体

Resumen de: WO2025129271A1

The claimed invention is to a lipid delivery vehicle for eliciting a tolerogenic immune response in a subject, comprising nuclear factor-KB (NF-KB) inhibitor and a peptide antigen, wherein the lipid delivery vehicle comprises 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and l-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG).

普鲁士蓝类似物纳米颗粒及其制备方法和应用

Resumen de: CN122537324A

本发明提出一种普鲁士蓝类似物纳米颗粒及其制备方法和应用，属于脑卒中领域及光催化技术领域。所述制备方法包括如下步骤：S1、采用共沉淀法，合成含有Cu、Ni、Co的具有S型异质结结构的Cu‑Ni Co PBAs纳米颗粒；S2、采用超声辅助吸附法，在Cu‑Ni Co PBAs纳米颗粒表面采用PLGA‑PEG‑CREKA修饰肽进行包裹，得Cu‑Ni Co PBAs‑C材料。本发明提出的添加生物修饰肽的普鲁士蓝类似物纳米材料(Cu‑Ni Co PBAs‑C)，通过其光催化产氢，用于缺血性脑卒中的治疗，以改善传统氢气治疗方法的弊端。

方法およびシステム

Resumen de: WO2025032322A1

A method of generating a plurality of different surface-decorated nanoparticles, decorated with different surface decoration, comprising: forming a plurality of microdroplets in a microfluidics device, each microdroplet comprising a nanoparticle and a respectively different macromolecule encoding a different surface decoration molecule; synthesising the surface decoration molecule, within each microdroplet, based on the macromolecule encoding the surface decoration molecule; conjugating the nanoparticle and the surface decoration molecule, within each microdroplet, to form surface decorated nanoparticles.

An artificial exosome for drug delivery and a preparation method thereof

Resumen de: NL4002163A

The invention relates to the technical field of medicine, and discloses an artificial exosome for drug delivery and a preparation method thereof. The invention uses PCL- PEG-PCL, DC-Chol, and TA-PEG-TA to construct a polymer core, loads OCT4 protein, siTrim28, and VC-Lip, forms a suspension through high-pressure-ultrasonic synergistic treatment and solvent evaporation curing, and then obtains the final product through dynamic film formation, multilayer self-assembly coating, gradient centrifugation purification, and hyaluronic acid anti-enzymatic degradation modification. The invention is significantly superior to artificial exosomes prepared by the prior art in four core indicators, namely structural stability, intelligent responsive release, targeting specificity, and anti-destruction capability.

乾燥及び長期保存用ポリヌクレオチド製剤の組成物、方法及び使用

Resumen de: WO2025029323A1

Embodiments of the present disclosure provide novel compositions and methods for making and using thermostable polynucleotide-containing formulations. In certain embodiments, compositions and methods are disclosed for creating thermostable polynucleotides and/or thermostable polynucleotides encoding at least one therapeutic agent for use in therapies for the treatment of health conditions in a subject. In some embodiments, compositions and methods are disclosed for creating thermostable polynucleotides for use in therapeutics, vaccines, and targeted gene therapies. In other embodiments, compositions and methods are disclosed for creating thermostable polynucleotides capable of being coated or encased for prolonged storage and/or timed-delivery.

筋肉特異的送達のためのイオン化可能な脂質

Resumen de: AU2024303863A1

The present invention provides an ionizable lipid for muscle-specific delivery, and specifically relates to a compound of formula (I), or an isotopic variant, tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further provides a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition thereof in muscle-specific nucleic acid delivery.

ジエステル脂質、ジエステル脂質を含有する脂質ナノ粒子、及びそれらの製剤

Resumen de: WO2025010504A1

Provided is a diester lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 10 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 5 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. (I)

親油性化合物を含む水性メソ粒子組成物の新規な製造方法

Resumen de: NL2035231B1

Described is a method for the preparation of an aqueous nanoparticle composition comprising a hydrophobic compound, comprising the steps of: a. Providing an emulsifier or a blend of emulsifiers in powder form; 10 b. Mixing one or more oils at a temperature above 40°C where all oils have become liquid, wherein said oils differ in melting temperature and which mixture comprises at least a sufficient amount of medium chain triglycerides to enable the composition formed in step g to be liquid at temperatures around about 4°C; 15 c. Adding the hydrophobic compound in any hydrophobic solvent to the oil mixture; d. Optionally letting the mixture cool down to room temperature; e. Adding the emulsifier powder and water to the oil mixture and letting the mixture emulsify, under optional agitation and heating to 30-40°C; 20 f. Subjecting the emulsified mixture to a sonication treatment comprising optionally mixing or fluidisation, until the average particle size of the mixture remains stable; g. Cooling down the sonicated mixture. and compositions produced by the above method. 25

経皮免疫療法のための方法およびシステム

Nº publicación: JP2026526895A 10/08/2026

Solicitante:

パスポートテクノロジーズ、インコーポレイテッド

Resumen de: WO2025024500A1

Disclosed herein are patches, methods, devices, and systems for delivering RNA encapsulated lipid nanoparticles into a subject. In some aspect, the patch includes a backing, a reservoir comprising lipid nanoparticles and one or more RNA molecules disposed within the reservoir, and a release liner. In other aspects, the method includes opening at least one channel in the subject's skin, applying the patch described herein, thereby delivering lipid nanoparticles to an immune cell.